CHENGDU KANGHONG PHARMACEUTICAL GROUP CO., LTD

Chengdu Kanghong Pharmaceutical Group Co., Ltd

002773

CNE1000020C4

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 23:00:00 25/06/2024 BST			5-day change	1st Jan Change
22.35 ^CNY	+3.62%		-1.97%	+21.20%

06-19	Kanghong Pharmaceutical's Unit Gets Nod to Market Conbercept Eye Injection in Myanmar	MT
06-04	Kanghong Pharmaceutical Gets Regulatory Nod for Pranoprofen Eye Drop	MT

Chengdu Kanghong Pharmaceutical Group Co., Ltd Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 28 May 2024

May 21, 2024

Chengdu Kanghong Pharmaceutical Group Co. Ltd. announced final cash dividend of CNY 3.80000000 per ten A shares (tax included) for the year 2023. Record date: 27 May 2024.

Ex-date: 28 May 2024. Payment date: 28 May 2024.

Latest news about Chengdu Kanghong Pharmaceutical Group Co., Ltd

Kanghong Pharmaceutical's Unit Gets Nod to Market Conbercept Eye Injection in Myanmar	06-19	MT
Kanghong Pharmaceutical Gets Regulatory Nod for Pranoprofen Eye Drop	06-04	MT
Chengdu Kanghong Pharmaceutical Group Co., Ltd Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 28 May 2024	05-21	CI
Kanghong Pharmaceutical's Unit Gets US FDA's Green Light to Test Macular Degeneration Drug	04-29	MT
Kanghong Pharmaceutical's Unit Gets Nod to Trial Macular Degeneration Drug	04-29	MT
Chengdu Kanghong Pharmaceutical Group Co., Ltd Proposes Final Cash Dividend for the Year 2023	04-24	CI
Chengdu Kanghong Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	04-24	CI
Chengdu Kanghong Pharmaceutical Group Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	04-24	CI
Kanghong Pharmaceutical's Mosapride Citrate Tablets Wins Centralized Procurement Bid	04-17	MT
Kanghong Pharmaceutical's Beijing Unit Gets China's Approval for Clinical Trials for Anti-Tumor Injection	03-06	MT
Kanghong Pharmaceutical's Unit Gets Nod to Trial Psoriasis Drug	02-28	MT
Kanghong Pharmaceutical Gets Nod for Registration of Escitalopram Oxalate Tablets	12-12	MT
Kanghong Pharma's Aripiprazole Oral Solution Chosen for China's Centralized Drug Procurement	11-08	MT
Kanghong Pharma Gets FDA Nod to Trial Drug Against Fatty Liver Disease	11-06	MT
Chengdu Kanghong Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	26/10/23	CI
Kanghong Pharmaceutical Gets US FDA's Clinical Trial Nod for Antidepressant	24/10/23	MT
Chengdu Kanghong Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	27/08/23	CI
Chengdu Kanghong Pharmaceutical Group Co., Ltd Announces Executive Changes	04/08/23	CI
Kanghong Pharma Gets Nod to Trial Antidepressant	20/07/23	MT
Chengdu Hongji Biotechnology Co., Ltd. announced that it expects to receive CNY 159.736344 million in funding from Chengdu Kanghong Pharmaceutical Group Co., Ltd, Chengdu Kangji Enterprise Management Consulting Partnership (Limited Partnership), Chengdu Kangyin Enterprise Management Consulting Partnership (Limited Partnership), Chengdu Kangzhi Technology Consulting Partnership (Limited Partnership)	11/07/23	CI
Kanghong Pharma Gets Continued Protection for Traditional Chinese Medicine	20/06/23	MT
Chengdu Kanghong Pharmaceutical Group Co., Ltd Announces Final Cash Dividend on Share A for 2022, Payable on June 6, 2023	30/05/23	CI
Chengdu Kanghong Pharmaceutical Group Co., Ltd Approves Cash Dividend for the Year 2022	24/05/23	CI
Chengdu Kanghong Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	27/04/23	CI
Chengdu Kanghong Pharma Wins Orphan Drug Designation in US	16/02/23	MT

Chart Chengdu Kanghong Pharmaceutical Group Co., Ltd

Duration

Period

Chart Chengdu Kanghong Pharmaceutical Group Co., Ltd

More charts

Chengdu Kanghong Pharmaceutical Group Co., Ltd is a China-based company principally engaged in the research, development, manufacture and distribution of Chinese patent medicines, chemical drugs and biological products. The Companyâs main products include Conbercept Ophthalmic Injection, Songling capsules conducive to blood vessels, Keluoxin capsules, venlafaxine hydrochloride capsules and sustained release tablets, aripiprazole tablets and orally disintegrating tablets, mosapride citrate tablets and dispersible tablets, dexzopiclone tablets, Shuganjieyu capsules, Danshu capsules and Yiqing capsules, among others. The Company distributes its products in domestic market.

Sector

Pharmaceuticals

Calendar

25/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CHENGDU KANGHONG PHARMACEUTICAL GROUP CO., LTD	+21.20%	2.73B
ELI LILLY AND COMPANY	+55.19%	815B
NOVO NORDISK A/S	+44.25%	654B
JOHNSON & JOHNSON	-6.52%	354B
MERCK & CO., INC.	+22.02%	337B
ABBVIE INC.	+10.63%	302B
ASTRAZENECA PLC	+18.45%	247B
ROCHE HOLDING AG	+2.09%	229B
NOVARTIS AG	+13.03%	219B
AMGEN INC.	+9.44%	171B

Other Pharmaceuticals